Ligand Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US53220K5048
USD
204.81
-6.18 (-2.93%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Dec'25
Sep'25
Jun'25
Mar'25
Dec'24
Sep'24
Jun'24
Net Sales
59.67
115.46
47.63
45.33
42.81
51.81
41.53
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
59.67
115.46
47.63
45.33
42.81
51.81
41.53
Raw Material Cost
11.09
11.90
11.16
13.11
11.10
10.71
11.16
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
1.78
0.91
1.15
0.87
0.88
0.74
1.27
Selling and Distribution Expenses
25.23
28.65
20.57
19.20
25.91
24.77
19.12
Other Expenses
0.17
2.01
0.54
4.92
0.35
0.49
0.41
Total Expenditure (Excl Depreciation)
39.83
61.56
38.31
82.39
41.42
41.16
35.64
Operating Profit (PBDIT) excl Other Income
19.8
53.9
9.3
-37.1
1.4000000000000001
10.700000000000001
5.8999999999999995
Other Income
29.94
11.23
3.93
-10.10
-23.38
-8.74
-45.22
Operating Profit (PBDIT)
58.12
74.08
22.59
-37.41
-12.47
11.78
-28.47
Interest
1.78
0.91
1.15
0.87
0.88
0.74
1.27
Exceptional Items
8.59
76.72
-1.28
-2.56
-16.62
-7.81
-26.29
Gross Profit (PBDT)
48.58
103.56
36.46
32.23
31.72
41.10
30.37
Depreciation
8.14
8.75
8.93
9.34
9.22
9.57
9.36
Profit Before Tax
56.78
141.14
11.22
-50.18
-39.20
-6.34
-65.39
Tax
12.00
23.86
6.38
-7.73
-8.11
0.83
-13.48
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
44.78
117.27
4.85
-42.45
-31.09
-7.17
-51.91
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
44.78
117.27
4.85
-42.45
-31.09
-7.17
-51.91
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
44.78
117.27
4.85
-42.45
-31.09
-7.17
-51.91
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
1,017.21
950.17
828.53
795.53
830.44
841.18
775.20
Earnings per share (EPS)
2.12
5.68
0.24
-2.21
-1.64
-0.39
-2.88
Diluted Earnings per share
2.12
5.68
0.24
-2.21
-1.64
-0.39
-2.88
Operating Profit Margin (Excl OI)
33.59%
46.85%
20.41%
-80.87%
3.94%
21.14%
17.8%
Gross Profit Margin
108.8%
129.81%
42.32%
-90.09%
-70.03%
6.23%
-134.92%
PAT Margin
75.06%
101.57%
10.18%
-93.64%
-72.62%
-13.84%
-124.99%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - QoQ
stock-summary

Net Sales

QoQ Growth in quarter ended Dec 2025 is -48.31% vs 142.65% in Sep 2025

stock-summary

Consolidate Net Profit

QoQ Growth in quarter ended Dec 2025 is -61.81% vs 2,343.75% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -55.10% vs 235.83% in Sep 2025

stock-summary

Interest

QoQ Growth in quarter ended Dec 2025 is 100.00% vs -25.00% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Ligand Pharmaceuticals, Inc. With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(USD)
Change(%)
Net Sales
59.67
53.72
5.95
11.08%
Other Operating Income
0.00
0.00
0.00
Total Operating income
59.67
53.72
5.95
11.08%
Raw Material Cost
11.09
6.08
5.01
82.40%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0.00
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
1.78
0.00
1.78
Selling and Distribution Expenses
25.23
34.15
-8.92
-26.12%
Other Expenses
0.17
4.09
-3.92
-95.84%
Total Expenditure (Excl Depreciation)
39.83
81.18
-41.35
-50.94%
Operating Profit (PBDIT) excl Other Income
19.84
-27.46
47.30
172.25%
Other Income
29.94
4.20
25.74
612.86%
Operating Profit (PBDIT)
58.12
-22.26
80.38
361.10%
Interest
1.78
0.00
1.78
Exceptional Items
8.59
0.00
8.59
Gross Profit (PBDT)
48.58
47.64
0.94
1.97%
Depreciation
8.14
0.99
7.15
722.22%
Profit Before Tax
56.78
-23.25
80.03
344.22%
Tax
12.00
-1.98
13.98
706.06%
Provisions and contingencies
0
0
0.00
Profit After Tax
44.78
-21.28
66.06
310.43%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
44.78
-21.28
66.06
310.43%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
44.78
-21.28
66.06
310.43%
Equity Capital
0
0
0.00
Face Value
0.00
0.00
0.00
Reserves
1,017.21
441.16
576.05
130.58%
Earnings per share (EPS)
2.12
-0.21
2.33
1,109.52%
Diluted Earnings per share
2.12
-0.21
2.33
1,109.52%
Operating Profit Margin (Excl OI)
33.59%
-51.12%
0.00
84.71%
Gross Profit Margin
108.80%
-41.44%
0.00
150.24%
PAT Margin
75.06%
-39.61%
0.00
114.67%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 5.97 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is -48.31% vs 142.65% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 39.49% vs 52.31% in Dec 2024

Quarterly - Consolidate Net Profit
Consolidate Net Profit 4.48 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is -61.81% vs 2,343.75% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 244.05% vs -270.88% in Dec 2024

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 2.82 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is -55.10% vs 235.83% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 158.72% vs 78.69% in Dec 2024

Quarterly - Interest
Interest 0.18 Million
in Dec 2025

Figures in Million
stock-summary

QoQ Growth in quarter ended Dec 2025 is 100.00% vs -25.00% in Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 is 100.00% vs 800.00% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 33.59%
in Dec 2025

Figures in %
stock-summary

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

stock-summary

YoY Growth in quarter ended Dec 2025 has improved from Dec 2024